spacer
home > pmps > winter 2017 > whats the outcome
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Whats the Outcome

The global delivery of healthcare has become more focused on medical outcomes, achieving results for patients and tying industry incentives to those results. As with any fundamental change in business structure, this is happening slowly and at different rates around the world. The case for change, however, is strong and compelling.

Population growth and rising incomes create further demand for access to healthcare; incidences of lifestyle-related health conditions like diabetes occur more frequently; and technological innovation continues to support increasing targeted disease and associated therapy identification, whether through genetic analysis or the discovery and commercialisation of large molecule therapies like biologics. The value of the ensuing biologics market is forecast to grow by 60%, rising to a value of $291 billion annually between 2014 and 2020.

With a stronger focus on outcomes, it will not be sufficient for biopharmaceutical innovators to only think about the elements of the solution – like devices and connected services, for example – shortly before market launch. A more rounded approach to creating value in healthcare delivery is needed. Tactically, this requires evaluating the system holistically (what results will we deliver, and why?) as well as each strategic element (how will the conclusion be achieved?) at least three years prior to the treatment being made available (before Phase 3). In doing so, outcome delivery and improvements become integrated parts of the answer. It is all part of providing end-to-end solutions that are focused on results, as delivering these will equal income in the future for the industry.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Bill Welch has over 25 years of contract design, development and manufacturing experience, primarily serving customers in the drug delivery, health technology and diagnostics markets. In his current capacity as Chief Technical Officer at Phillips-Medisize, he leads a global, over-500 person development, engineering, tooling, programme management and validation organisation with more than 75 concurrent schemes. Bill has been with Phillips-Medisize since 2002.
spacer
Bill Welch
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement